Brief Report : Clinical Outcomes by Infusion Timing of Immune Checkpoint Inhibitors in Patients With Locally Advanced NSCLC
© 2024 The Authors..
Introduction: Previous studies reported an association between immune checkpoint inhibitor infusion timing and the treatment effect in metastatic NSCLC. The present study assessed the association between durvalumab infusion timing and survival outcomes in patients with locally advanced NSCLC.
Methods: Patients receiving durvalumab after chemoradiotherapy for locally advanced NSCLC at a single institution were retrospectively analyzed, and the association of the proportion of durvalumab infusions greater than or equal to 20% versus less than 20% after 3 PM with progression-free survival (PFS) and overall survival was assessed.
Results: A total of 82 patients were included, with a median age of 69 years (interquartile range, 62-74 years); of these, 67 patients (82%) were of male sex, and 78 patients (95%) had a history of smoking. The median number of durvalumab infusions per patient was 16 (interquartile range, 8-24). Patients with at least 20% of their durvalumab infusions after 3 PM (n = 12/82, 15%) had a significantly shorter PFS than those who did not (median: 7.4 mo versus not available [NA]; hazard ratio [HR], 2.43; 95% confidence interval [CI]: 1.11-5.34, p = 0.027), whereas overall survival was shorter among the former compared with the latter group (median: 22.4 versus NA; HR, 1.80; 95% CI: 0.73-4.42, p = 0.20). In addition, both backward stepwise multivariable analysis and propensity score-matching analysis revealed that receiving at least 20% of durvalumab infusions after 3 PM was significantly associated with worse PFS (HR, 2.54; 95% CI: 1.03-5.67, p = 0.047; and HR, 4.64; 95% CI: 1.95-11.04; p < 0.001, respectively).
Conclusions: The time of day of durvalumab infusions may impact survival outcomes in patients with locally advanced NSCLC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:5 |
|---|---|
| Enthalten in: |
JTO clinical and research reports - 5(2024), 4 vom: 18. Apr., Seite 100659 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hirata, Tsuyoshi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chronotherapy |
|---|
| Anmerkungen: |
Date Revised 11.04.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.jtocrr.2024.100659 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370855396 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370855396 | ||
| 003 | DE-627 | ||
| 005 | 20240411232929.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240410s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jtocrr.2024.100659 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1372.xml |
| 035 | |a (DE-627)NLM370855396 | ||
| 035 | |a (NLM)38596201 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hirata, Tsuyoshi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Brief Report |b Clinical Outcomes by Infusion Timing of Immune Checkpoint Inhibitors in Patients With Locally Advanced NSCLC |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 11.04.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2024 The Authors. | ||
| 520 | |a Introduction: Previous studies reported an association between immune checkpoint inhibitor infusion timing and the treatment effect in metastatic NSCLC. The present study assessed the association between durvalumab infusion timing and survival outcomes in patients with locally advanced NSCLC | ||
| 520 | |a Methods: Patients receiving durvalumab after chemoradiotherapy for locally advanced NSCLC at a single institution were retrospectively analyzed, and the association of the proportion of durvalumab infusions greater than or equal to 20% versus less than 20% after 3 PM with progression-free survival (PFS) and overall survival was assessed | ||
| 520 | |a Results: A total of 82 patients were included, with a median age of 69 years (interquartile range, 62-74 years); of these, 67 patients (82%) were of male sex, and 78 patients (95%) had a history of smoking. The median number of durvalumab infusions per patient was 16 (interquartile range, 8-24). Patients with at least 20% of their durvalumab infusions after 3 PM (n = 12/82, 15%) had a significantly shorter PFS than those who did not (median: 7.4 mo versus not available [NA]; hazard ratio [HR], 2.43; 95% confidence interval [CI]: 1.11-5.34, p = 0.027), whereas overall survival was shorter among the former compared with the latter group (median: 22.4 versus NA; HR, 1.80; 95% CI: 0.73-4.42, p = 0.20). In addition, both backward stepwise multivariable analysis and propensity score-matching analysis revealed that receiving at least 20% of durvalumab infusions after 3 PM was significantly associated with worse PFS (HR, 2.54; 95% CI: 1.03-5.67, p = 0.047; and HR, 4.64; 95% CI: 1.95-11.04; p < 0.001, respectively) | ||
| 520 | |a Conclusions: The time of day of durvalumab infusions may impact survival outcomes in patients with locally advanced NSCLC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Chronotherapy | |
| 650 | 4 | |a Circadian rhythms | |
| 650 | 4 | |a Durvalumab | |
| 650 | 4 | |a Immunotherapy | |
| 650 | 4 | |a Lung cancer | |
| 700 | 1 | |a Uehara, Yuji |e verfasserin |4 aut | |
| 700 | 1 | |a Hakozaki, Taiki |e verfasserin |4 aut | |
| 700 | 1 | |a Kobayashi, Takayuki |e verfasserin |4 aut | |
| 700 | 1 | |a Terashima, Yuto |e verfasserin |4 aut | |
| 700 | 1 | |a Watanabe, Kageaki |e verfasserin |4 aut | |
| 700 | 1 | |a Yomota, Makiko |e verfasserin |4 aut | |
| 700 | 1 | |a Hosomi, Yukio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t JTO clinical and research reports |d 2020 |g 5(2024), 4 vom: 18. Apr., Seite 100659 |w (DE-627)NLM315014199 |x 2666-3643 |7 nnns |
| 773 | 1 | 8 | |g volume:5 |g year:2024 |g number:4 |g day:18 |g month:04 |g pages:100659 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jtocrr.2024.100659 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 5 |j 2024 |e 4 |b 18 |c 04 |h 100659 | ||